Palmitoylethanolamide: A Potential Alternative to Cannabidiol
ReviewHumans
- Design
- Review
- Subjects
- Not stated in the abstract
- Dose used in the study
- Not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- How palmitoylethanolamide compares with cannabidiol on mechanism, evidence, safety and regulatory status
What the authors reported
CBD's evidence base is insufficient and its regulatory status unclear, the authors say. PEA, an endocannabinoid-like lipid acting mainly through PPAR-alpha and possibly the endocannabinoid system, has anti-inflammatory, analgesic and neuroprotective properties, and the authors conclude it is an alternative to CBD with a favourable safety profile.
Limits of this study
A narrative review with no new data and no trial numbers in the abstract. Conflicts are not stated in the abstract; the author group has published with Gencor, a palmitoylethanolamide supplier, in other papers.
Source
PubMed 34842030 · doi:10.1080/19390211.2021.2005733
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.